Free Trial
NASDAQ:MTEM

Molecular Templates (MTEM) Stock Price, News & Analysis

Molecular Templates logo

About Molecular Templates Stock (NASDAQ:MTEM)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
30,647 shs
Average Volume
4.20 million shs
Market Capitalization
$1,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Molecular Templates Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
23rd Percentile Overall Score

MTEM MarketRank™: 

Molecular Templates scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Molecular Templates.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Molecular Templates is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Molecular Templates is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for MTEM.
  • Dividend Yield

    Molecular Templates does not currently pay a dividend.

  • Dividend Growth

    Molecular Templates does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MTEM.
  • News Sentiment

    Molecular Templates has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Molecular Templates this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Molecular Templates insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.90% of the stock of Molecular Templates is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.47% of the stock of Molecular Templates is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Molecular Templates' insider trading history.
Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

MTEM Stock News Headlines

Nasdaq to file Form 25-NSE with SEC to delist Molecular Templates
Secret financial plot unfolding in Washington DC… [DEVELOPING]
What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. You see, I’ve recently uncovered a secret financial plot unfolding in Washington DC…
Molecular Templates Announces Key Leadership Transition
See More Headlines

MTEM Stock Analysis - Frequently Asked Questions

Molecular Templates, Inc. (NASDAQ:MTEM) posted its earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) EPS for the quarter, missing the consensus estimate of ($5.67) by $2.43. The biotechnology company had revenue of $2.38 million for the quarter, compared to the consensus estimate of $15.69 million. Molecular Templates had a negative net margin of 61.35% and a negative trailing twelve-month return on equity of 260.50%.

Molecular Templates's stock reverse split on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Templates investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/15/2021
Today
4/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MTEM
Employees
260
Year Founded
2009

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,120,000.00
Pretax Margin
-61.39%

Debt

Sales & Book Value

Annual Sales
$23.48 million
Price / Cash Flow
N/A
Book Value
$0.78 per share
Price / Book
N/A

Miscellaneous

Free Float
5,669,000
Market Cap
$1,000.00
Optionable
No Data
Beta
1.53

Social Links

Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:MTEM) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners